Posted by Michael Wonder on 13 Mar 2023
Haihe Biopharma announces gumarontinib receives approval from the NMPA of China for the treatment of locally advanced or metastatic NSCLC with MET exon 14 skipping mutation
8 March 2023 - Haihe Biopharma today announced that the NMPA of China has given conditional approval to gumarontinib, an oral highly selective mesenchymal-epithelial transition (MET) inhibitor and a Category 1 innovative new chemical drug that the Company has co-developed with Shanghai Institute of Material Medica, Chinese Academy of Sciences, for the treatment of adult patients with locally advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutation.
Gumarontinib was granted by NMPA as breakthrough therapy program and reviewed under priority review procedure.
